DrugPatentWatch Database Preview
JADENU SPRINKLE Drug Profile
When do Jadenu Sprinkle patents expire, and when can generic versions of Jadenu Sprinkle launch?
Jadenu Sprinkle is a drug marketed by Novartis Pharms Corp and is included in one NDA. There is one patent protecting this drug.
This drug has forty-eight patent family members in thirty-four countries.
The generic ingredient in JADENU SPRINKLE is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.
Summary for JADENU SPRINKLE
| International Patents: | 48 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 88 |
| Patent Applications: | 350 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for JADENU SPRINKLE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for JADENU SPRINKLE |
| DailyMed Link: | JADENU SPRINKLE at DailyMed |
Synonyms for JADENU SPRINKLE
| 1044764-54-6 |
| 1133425-75-8 |
| 201530-41-8 |
| 4-((3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid |
| 4-((3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid |
| 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid |
| 4-[(3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid |
| 4-[(3Z,5E)-3,5-Bis(6-Oxo-2,4-cyclohexadien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid, AldrichCPR |
| 4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid |
| 4-[3,5-bis(2-hydroxyphenyl) |
| 4-[3,5-Bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid |
| 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid |
| 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid |
| 4-[3,5-bis(6-oxidanylidenecyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid |
| 4-[3,5-bis(6-oxo-1-cyclohexa-2,4-dienylidene)-1,2,4-triazolidin-1-yl]benzoic acid |
| 4-{5-[(1E)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-3-[(1Z)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-1,2,4-TRIAZOLIDIN-1-YL}BENZOIC ACID |
| 530D418 |
| A814288 |
| AB0020007 |
| AB0073018 |
| AB01565800_02 |
| AB1008603 |
| AC-8972 |
| AC1NUU0E |
| AC1O1JMP |
| ACM1133425758 |
| AKOS015855839 |
| AKOS015902587 |
| AKOS025312553 |
| AN-5418 |
| BC677677 |
| BCP9000594 |
| BDBM50088376 |
| Benzoic acid, 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)- |
| Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]- |
| BOFQWVMAQOTZIW-UHFFFAOYSA-N |
| C21H15N3O4 |
| CAS-201530-41-8 |
| CGP-72670 |
| CHEBI:49005 |
| CHEMBL550348 |
| CS-0901 |
| CTK8F0690 |
| D03669 |
| D0Q5UQ |
| DB01609 |
| Deferasirox |
| Deferasirox (Exjade) |
| Deferasirox (JAN/USAN/INN) |
| Deferasirox [USAN:INN:JAN] |
| Deferasirox [USAN:INN] |
| Deferasirox-d4 |
| Deferasirox, ICL670 |
| Deferasiroxum |
| Deferasiroxum [INN-Latin] |
| DR002074 |
| DSSTox_CID_28522 |
| DSSTox_GSID_48596 |
| DSSTox_RID_82794 |
| DTXSID1048596 |
| Exjade |
| Exjade (TN) |
| F0001-2380 |
| FT-0601564 |
| HE297142 |
| HE323479 |
| HMS3655A04 |
| HSDB 7844 |
| HY-17359 |
| I14-1968 |
| ICL 670 |
| ICL 670A |
| ICL-670 |
| ICL-670A |
| ICL670 |
| ICL670A |
| J-013060 |
| Jadenu |
| Jadenu (TN) |
| KB-49640 |
| KE-0220 |
| KS-00000G02 |
| LS-186571 |
| LS-187785 |
| MFCD09751362 |
| MFCD09951804 |
| MLS003915634 |
| MLS006010080 |
| MolPort-006-392-553 |
| MolPort-028-744-623 |
| NCGC00181754-01 |
| NCGC00263572-01 |
| PubChem20503 |
| s1712 |
| SCHEMBL1071867 |
| SCHEMBL61756 |
| SCHEMBL62042 |
| SMR002544689 |
| SR-01000931971 |
| SR-01000931971-2 |
| Tox21_112926 |
| Tox21_112926_1 |
| UNII-V8G4MOF2V9 |
| V0697 |
| V8G4MOF2V9 |
| W-5422 |
| ZINC100022643 |
| ZINC100504305 |
| ZINC100504309 |
| ZINC1481815 |
| ZINC14880008 |
US Patents and Regulatory Information for JADENU SPRINKLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-001 | May 18, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-002 | May 18, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-003 | May 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for JADENU SPRINKLE
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Slovenia | 914118 | ➤ Sign Up |
| Australia | 718037 | ➤ Sign Up |
| African Intellectual Property Organization (OAPI) | 10946 | ➤ Sign Up |
| Taiwan | 533205 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for JADENU SPRINKLE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0914118/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005 |
| 2007001 | Lithuania | ➤ Sign Up | PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828 |
| 0 | Finland | ➤ Sign Up | |
| 2006 00035 | Denmark | ➤ Sign Up | |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
